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This is a case report of a patient with idiopathic gingival hyperplasia and an undiagnosed genetic disorder that demonstrated static
encephalopathy, mental retardation, developmental delay, seizures, hypotonia, and severe gingival hypertrophy. The clinical dental
management and attempts to obtain a genetic diagnosis are described.
1.Introduction
Gingival hyperplasia can occur as an isolated form or
part of a syndrome. Complications associated with gingival
overgrowth may include retained primary teeth, delayed
eruption of permanent teeth, increased distal spacing, drift-
ing of teeth, poor plaque control, poor mastication, aﬀected
speech, esthetics, and malocclusion [1–4]. Several etiologies
have been reported including drug-induced, hereditary,
hormones-related (pregnancy, growth-hormone), inﬂam-
mation, systemic (leukemia, neuroﬁbromatosis), idiopathic,
and syndrome associated. Depending on the cause, the
overgrowth may vary in clinical presentation, severity, onset,
and duration.
Cyclosporine, phenytoin, and nifedipine are the most
common drugs associated with drug-induced gingival over-
growth [4–10]. The aﬀect is more commonly observed in
children than adults, possibly due to immature ﬁbroblasts
havingincreasedsensitivitytocyclosporine[8,9].Synergistic
eﬀectsofnifedipineandcyclosporinehavealsobeenreported
[11, 12].
Rare cases of sodium valproate-related gingival enlarge-
ment have also been reported, including one involving
infantile gingival overgrowth at birth secondary to maternal
sodium valproate use [13–16]. However, a clinical study
involving epileptic adults receiving sodium valproate and a
control group showed no signiﬁcant diﬀerences between the
two groups on any parameters assessed [6].
Hereditary gingival hyperplasia is a slowly progressive,
generalized, severe gingival enlargement involving maxillary
and mandibular arches. The pink ﬁrm gingiva is ﬁbrotic and
nonhemorrhagic. Severity varies and may cover part/all of
the crowns of the erupted teeth. It usually develops around
the eruption of permanent teeth and is rarely present at
birth. The most common mode of inheritance is autosomal
dominant with variable penetrance [17–19]. The syndrome
most commonly associated with gingival hyperplasia is
gingivalﬁbromatosiswithgeneralizedhypertrichosis,mental
retardation, and tonic-clonic seizures [20, 21]. Isolated cases
of gingival ﬁbromatosis associated with amelogenesis imper-
fect and aggressive periodontitis have also been reported
[2, 22, 23]. Conditions known to be associated with gingival
hyperplasia are summarized in Table 1.
Idiopathicgingivalhyperplasiahasbeendescribedinsev-
eral case reports. The clinical presentation of the gingiva was
similar to that of hereditary gingival hyperplasia but did not
have a contributory medical or family history [1–3]. General
histological ﬁndings include normal overlying epithelium,
rete pegs extending deep into underlying connective tissues
with some areas of hyperplasia, proliferating dense ﬁbrous2 Case Reports in Dentistry
CT with increased cellularity and coarse collagenous ﬁber
bundles and hyperkeratosis and acanthosis with elongated
papillae [1, 2, 18].
The purpose of this paper is to present a case report
of a patient with idiopathic gingival hyperplasia and an
undiagnosed medical condition that demonstrated static
encephalopathy, mental retardation, developmental delay,
seizures, and hypotonia.
2.CaseReport
A 2-month old Caucasian male was admitted to the hospital
due to right perihilar pneumonia with hyperaeration and
three months later was diagnosed with chicken pox. He also
presented with global delays, dysmorphic features including
craniofacial asymmetry, apparently secondary to postural
position, with ﬂattening of the left occiput, cup-shaped
external ears, broad nasal bridging and small upturned tip of
the nose, smooth philtrum, umbilical hernia, undescended
testes, lax abdominal muscles, overlapping toes, and broad
and thickened hands and feet. He was subsequently referred
forgeneticandneurologicevaluation.Peripheralbloodtaken
for chromosomal analysis revealed no abnormalities, includ-
ing negative results for Fragile X syndrome. A computed
tomography (CT) scan of the head revealed atrophic changes
of the brain, with no hemorrhage or evidence of masses or
recent infarction.
The child’s mother reported an uncomplicated preg-
nancy and denied prenatal exposure to tobacco, alcohol, and
drugs. The only medication taken during pregnancy was
a suppository for nausea. She also reported no exposure
to radiation and no illness during her pregnancy. The
birth history was unremarkable, with 40-week gestation and
normal spontaneous vaginal delivery. Prenatal history was
uneventful with no infection, bleeding, or unusual event.
The patient exhibited no jaundice or cyanosis at birth.
There was no information about newborn screening for
PKU,hypothyroidism,orgalactosemia.Nohistorytosuggest
consanguinity was reported by the parents and there was no
family history to suggest birth defects or mental retardation.
The aﬀected child had a healthy 2.5-year-old female sibling.
The patient suﬀered from repeated respiratory infection
over the next 4-5 months and had an adenoidectomy at ten
months of age. He continued to demonstrate developmental
delays, spasticity of the upper and lower extremities, and
poor muscle tone. A neurology evaluation reported that
the growth and developmental course did not support a
progressive or degenerative condition. It was suggested that
the overall developmental delay was the result of some
unknown intrauterine encephalopathy or developmental
anomaly of the brain.
At 21 months of age the patient was seen in the pediatric
clinic for well child care. It was reported that he had been
seen by a dentist and there was no evidence of dental
eruption. He was prescribed with theophylline, albuterol
sulfate, and Naldecon for his asthma-like symptoms and
recurrent respiratory infections. The patient was referred at
24 months of age to an occupational therapist to assist with
mouth motions and lip movements. He was reported to have
Figure 1: Pre-operative picture of gingival hyperplasia at 4 years/6
months of age.
Figure 2: Immediate post-gingivectomy.
severe generalized hypotonia and hypertrophic gums with
only four partially erupted mandibular incisors.
Four months later, the patient was seen at a developmen-
tal evaluation center. Findings included diﬀuse encephalopa-
thy of unknown origin, dysmorphic features, microcephaly,
generalized hypotonia, and oral-motor dysfunction. There
were multidisciplinary follow-up visits with an ophthalmol-
ogist, urologist, dentist, audiologist, speech, and language
therapist. The patient was referred to the Department of
Pediatric Dentistry, University of North Carolina School
of Dentistry for evaluation and management of gingival
hyperplasia. At 4.5 years of age, a full mouth gingivectomy
was completed using a carbon dioxide laser and electro-
surgery, under general anesthesia. The patient tolerated the
procedurewellandwasdischargedthefollowingday(Figures
1 and 2). He was seen 10 days after-surgery for evaluation.
T h ep o s t o p e r a t i v ec o u r s ew a su n e v e n t f u l .O r a lh y g i e n ew a s
emphasized to parents (Figure 3).
When examined 16 months later (6 years of age), the
gingival hyperplasia had recurred for on both maxillary and
mandibular dental arches (Figure 4). The parent provided
oral hygiene for the patient was excellent. The patient was
taking divalproex sodium for his seizure disorder. Again, a
full mouth gingivectomy and extraction of some primaryCase Reports in Dentistry 3
Table 1
Conditions associated with gingival hyperplasia Features
Autosomal recessive
I-cell disease (Mucolipidosis II) Mental and physical retardation; appears prior to eruption of primary
teeth
Ramon Syndrome Gingival ﬁbromatosis, hypertrichosis, cherubism, mental retardation,
and seizures
Juvenile hyaline ﬁbromatosis
(Murray-Peretic-Drescher syndrome)
Multiple hyaline ﬁbromas, white papules on the skin, ﬂexion
contractures, osteolytic bone lesions, and gingival ﬁbromatosis
Alpha-Mannosidosis
A type of oligosaccharidosis, delayed early motor development, mild
hypotonia, hypoplastic bones, macroglossia, hepatosplenomegaly,
and gingival enlargement
Donohue syndrome (Leprechaunism) Failure to thrive, unusual facies, facial hirsutism, retarded bone age,
and insulin resistance with glucose intolerance and hyperinsulinemia
Cross syndrome Hypopigmentation, microphthalmia, mental retardation, athetosis,
and gingival ﬁbromatosis
Hornova-Dluhosova syndrome Oral and conjunctival amyloidosis and mental retardation
Autosomal dominant
Zimmerman-Laband syndrome Gingival ﬁbromatosis, ear, bone, nail defects, hepatosplenomegaly
Rutherford syndrome Gingival ﬁbromatosis and corneal dystrophy, failure of tooth eruption
Jones syndrome Gingival ﬁbromatosis with sensorineural hearing loss
Other
Borronedermato-cardio-skeletal syndrom
(Autosomal recessive/X-linked recessive)
Coarse facies, thick skin, acne conglobata, gingival enlargement,
osteolysis, camptodactyly, and mitral valve prolapsed
Figure 3: 10-day after surgery.
anterior teeth that were near exfoliation was provided under
general anesthesia. The primary teeth and multiple gingiva
specimens were sent to pathology. Dense ﬁbrous connective
gingiva tissue with no Periodic acid-Schiﬀ (PAS) stainable
material in the specimen was reported. A pediatric geneticist
in the Division of Pediatric Genetics and Metabolism
recommended various tests for possible rare storage dis-
orders. Chromosomal testing, mucopolysaccharides (MPS),
and lysosomal disorder screenings were negative. Peritoneal
and skin biopsies were obtained and sent to cytogenetics
for investigation. Results of the various tests revealed no
abnormalities and no deﬁnitive diagnosis were made.
Over the next three years, the patient was subjected
to his third and fourth gingivectomy procedures under
general anesthesia due to recurrence of gingival hyperplasia.
At 11 years 4 months of age, he was subjected to a ﬁfth
Figure 4: Recurrence of gingival hyperplasia at 6 years of age
(primary dentition).
gingivectomy procedure. He was still taking divalproex
sodium for his seizure disorder.
The patient presented for another dental examination
at the age of 16 years. He continued to demonstrate
gingival hyperplasia. A consult from the Department of
Oral and Maxillofacial Surgery was obtained. The suggested
treatment was extraction of all teeth in attempt to reduce the
current gingival hyperplasia, remove excess alveolar bone,
and possibly prevent future gingival overgrowth versus no
treatment.There wasno subsequentfollowupby the parents.
Four years later (20 years of age), the patient and his
parents returned for another dental evaluation with regard
to the continued gingival hyperplasia (Figure 5). His open
bite and lip incompetence had increased from the last dental
visit. The oral surgeon from the Department of Oral and4 Case Reports in Dentistry
Figure 5: Recurrence of gingival hyperplasia at 16 years of age
(permanent dentition).
Maxillofacial Surgery was again consulted who suggested
that total odontectomy and alveoplasty was the treatment
of choice. The parents agreed but the family had moved to
another state and chose to seek deﬁnitive dental care closer
to their home.
3. Discussion
Gingival hyperplasia is thought to be caused by one or more
sources.Theseincludeanincreaseinproliferationofresident
tissue ﬁbroblasts, a reduced level of metalloproteinases
synthesis (MMP-1 and MMP-2), resulting in low levels of
extracellular matrix-degrading, an increase in collagen type I
production, heat-shock protein 47 (hsp47) production, and
other extracellular matrix components [19].
Gagliano et al. [3] suggested that gingival hyperplasia
of diﬀerent etiologies may have diﬀerent mechanisms of
overgrowth. The likely mechanism of idiopathic gingival
hyperplasia may be increased collagen deposition as a
consequence of post translational mechanisms. The increase
in collagen cross-links renders it less susceptibility to MMP
degradation, favoring its accumulation in the gingival con-
nective compartment. Cyclosporine-induced gingival hyper-
plasia is associated with a decrease in the breakdown of
interstitialcollagenwithalowlevelofMMP,whilehereditary
gingival ﬁbromatosis demonstrates an activated ﬁbroblasts
phenotype.
In this case report, the patient was presented with static
encephalopathy of unknown origin, dysmorphic features,
microcephaly, generalized hypotonia, and seizure disorder.
Multiple tests were completed in an attempt to diagnose
his condition, but no genetic abnormalities were detected.
The patient also had delayed eruption of his primary teeth,
with no primary teeth present at 21 months old, and only
four mandibular incisors at 24 months of age. Gingival
hyperplasia of unknown etiology was ﬁrst noted at 24
months of age and before he was placed on divalproex
sodium for seizure disorder. This gingiva growth continued
to recur throughout the years, resulting in increased lip
incompetence and overbite. The etiology of the patient’s gin-
gival hyperplasia remains unknown. With no family history
and no apparent association with any medical syndromes,
the impression is that the gingival hyperplasia is idiopathic
in nature and possibly exacerbated by some drug inﬂuence
from divalproex sodium, which has been reported to have
controversial eﬀects on gingival tissues [6, 13–16]. It could
also be a rare mutation or other hereditary disorder with
some variance in expression such that other family members
are not aﬀected. However, this could not be conﬁrmed as no
genetic testing was completed on the family members.
Management of gingival hyperplasia depends on the
cause of the condition. Drug-induced gingival hyperpla-
sia may improve with substitution of other drugs that
rarely aﬀect the gingiva, such as barbiturates, valproic
acid, and tacrolimus [6, 24–29]. Use of antibiotics such as
metronidazole and azithromycin for cyclosporine-induced
gingival hyperplasia has been reported [30–32]. In general,
reinforcement of good home care oral hygiene regimens and
periodic professional surgical excision of gingival are the
treatments of choice [1–3, 19, 33].
The present case describes a patient with an undiagnosed
medical condition associated with idiopathic gingival hyper-
plasia and its management. It demonstrates the complex
nature of many genetic disorders that have not yet been
described but present treatment challenges.
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